Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 16 entries
Sorted by: Best Match Show Resources per page
Phospholipid nanoparticles: Therapeutic potentials against atherosclerosis via reducing cholesterol crystals and inhibiting inflammation.

EBioMedicine

Luo Y, Guo Y, Wang H, Yu M, Hong K, Li D, Li R, Wen B, Hu D, Chang L, Zhang J, Yang B, Sun D, Schwendeman AS, Eugene Chen Y.
PMID: 34879325
EBioMedicine. 2021 Dec 05;74:103725. doi: 10.1016/j.ebiom.2021.103725. Epub 2021 Dec 05.

BACKGROUND: Atherosclerosis-related cardiovascular diseases (CVDs) are the leading cause of mortality worldwide. Cholesterol crystals (CCs) induce inflammation in atherosclerosis and are associated with unstable plaques and poor prognosis, but no drug can remove CCs in the clinic currently.METHODS: We...

Cite
Luo Y, Guo Y, Wang H, et al. Phospholipid nanoparticles: Therapeutic potentials against atherosclerosis via reducing cholesterol crystals and inhibiting inflammation. EBioMedicine. 2021;74:103725doi: 10.1016/j.ebiom.2021.103725.
Luo, Y., Guo, Y., Wang, H., Yu, M., Hong, K., Li, D., Li, R., Wen, B., Hu, D., Chang, L., Zhang, J., Yang, B., Sun, D., Schwendeman, A. S., & Eugene Chen, Y. (2021). Phospholipid nanoparticles: Therapeutic potentials against atherosclerosis via reducing cholesterol crystals and inhibiting inflammation. EBioMedicine, 74103725. https://doi.org/10.1016/j.ebiom.2021.103725
Luo, Yonghong, et al. "Phospholipid nanoparticles: Therapeutic potentials against atherosclerosis via reducing cholesterol crystals and inhibiting inflammation." EBioMedicine vol. 74 (2021): 103725. doi: https://doi.org/10.1016/j.ebiom.2021.103725
Luo Y, Guo Y, Wang H, Yu M, Hong K, Li D, Li R, Wen B, Hu D, Chang L, Zhang J, Yang B, Sun D, Schwendeman AS, Eugene Chen Y. Phospholipid nanoparticles: Therapeutic potentials against atherosclerosis via reducing cholesterol crystals and inhibiting inflammation. EBioMedicine. 2021 Dec 05;74:103725. doi: 10.1016/j.ebiom.2021.103725. Epub 2021 Dec 05. PMID: 34879325.
Copy Download .nbib Format: NLM
Acetyl-CoA production by specific metabolites promotes cardiac repair after myocardial infarction via histone acetylation.

eLife

Lei I, Tian S, Gao W, Liu L, Guo Y, Tang P, Chen E, Wang Z.
PMID: 34939931
Elife. 2021 Dec 23;10. doi: 10.7554/eLife.60311.

Myocardial infarction (MI) is accompanied by severe energy deprivation and extensive epigenetic changes. However, how energy metabolism and chromatin modifications are interlinked during MI and heart repair has been poorly explored. Here, we examined the effect of different carbon...

Cite
Lei I, Tian S, Gao W, et al. Acetyl-CoA production by specific metabolites promotes cardiac repair after myocardial infarction via histone acetylation. Elife. 2021;10doi: 10.7554/eLife.60311.
Lei, I., Tian, S., Gao, W., Liu, L., Guo, Y., Tang, P., Chen, E., & Wang, Z. (2021). Acetyl-CoA production by specific metabolites promotes cardiac repair after myocardial infarction via histone acetylation. eLife, 10. https://doi.org/10.7554/eLife.60311
Lei, Ienglam, et al. "Acetyl-CoA production by specific metabolites promotes cardiac repair after myocardial infarction via histone acetylation." eLife vol. 10 (2021). doi: https://doi.org/10.7554/eLife.60311
Lei I, Tian S, Gao W, Liu L, Guo Y, Tang P, Chen E, Wang Z. Acetyl-CoA production by specific metabolites promotes cardiac repair after myocardial infarction via histone acetylation. Elife. 2021 Dec 23;10. doi: 10.7554/eLife.60311. PMID: 34939931.
Copy Download .nbib Format: NLM
Phospholipid nanoparticles: Therapeutic potentials against atherosclerosis via reducing cholesterol crystals and inhibiting inflammation.

EBioMedicine

Luo Y, Guo Y, Wang H, Yu M, Hong K, Li D, Li R, Wen B, Hu D, Chang L, Zhang J, Yang B, Sun D, Schwendeman AS, Eugene Chen Y.
PMID: 34879325
EBioMedicine. 2021 Dec 05;74:103725. doi: 10.1016/j.ebiom.2021.103725. Epub 2021 Dec 05.

BACKGROUND: Atherosclerosis-related cardiovascular diseases (CVDs) are the leading cause of mortality worldwide. Cholesterol crystals (CCs) induce inflammation in atherosclerosis and are associated with unstable plaques and poor prognosis, but no drug can remove CCs in the clinic currently.METHODS: We...

Cite
Luo Y, Guo Y, Wang H, et al. Phospholipid nanoparticles: Therapeutic potentials against atherosclerosis via reducing cholesterol crystals and inhibiting inflammation. EBioMedicine. 2021;74:103725doi: 10.1016/j.ebiom.2021.103725.
Luo, Y., Guo, Y., Wang, H., Yu, M., Hong, K., Li, D., Li, R., Wen, B., Hu, D., Chang, L., Zhang, J., Yang, B., Sun, D., Schwendeman, A. S., & Eugene Chen, Y. (2021). Phospholipid nanoparticles: Therapeutic potentials against atherosclerosis via reducing cholesterol crystals and inhibiting inflammation. EBioMedicine, 74103725. https://doi.org/10.1016/j.ebiom.2021.103725
Luo, Yonghong, et al. "Phospholipid nanoparticles: Therapeutic potentials against atherosclerosis via reducing cholesterol crystals and inhibiting inflammation." EBioMedicine vol. 74 (2021): 103725. doi: https://doi.org/10.1016/j.ebiom.2021.103725
Luo Y, Guo Y, Wang H, Yu M, Hong K, Li D, Li R, Wen B, Hu D, Chang L, Zhang J, Yang B, Sun D, Schwendeman AS, Eugene Chen Y. Phospholipid nanoparticles: Therapeutic potentials against atherosclerosis via reducing cholesterol crystals and inhibiting inflammation. EBioMedicine. 2021 Dec 05;74:103725. doi: 10.1016/j.ebiom.2021.103725. Epub 2021 Dec 05. PMID: 34879325; PMCID: PMC8654800.
Copy Download .nbib Format: NLM
The histone demethylase Kdm6b regulates the maturation and cytotoxicity of TCRαβ.

Cell death and differentiation

Zhang H, Hu Y, Liu D, Liu Z, Xie N, Liu S, Zhang J, Jiang Y, Li C, Wang Q, Chen X, Ye D, Sun D, Zhai Y, Yan X, Liu Y, Chen CD, Huang X, Eugene Chin Y, Shi Y, Wu B, Zhang X.
PMID: 34999729
Cell Death Differ. 2022 Jan 09; doi: 10.1038/s41418-021-00921-w. Epub 2022 Jan 09.

Intestinal intraepithelial lymphocytes (IELs) are distributed along the length of the intestine and are considered the frontline of immune surveillance. The precise molecular mechanisms, especially epigenetic regulation, of their development and function are poorly understood. The trimethylation of histone...

Cite
Zhang H, Hu Y, Liu D, et al. The histone demethylase Kdm6b regulates the maturation and cytotoxicity of TCRαβ. Cell Death Differ. 2022;doi: 10.1038/s41418-021-00921-w.
Zhang, H., Hu, Y., Liu, D., Liu, Z., Xie, N., Liu, S., Zhang, J., Jiang, Y., Li, C., Wang, Q., Chen, X., Ye, D., Sun, D., Zhai, Y., Yan, X., Liu, Y., Chen, C. D., Huang, X., Eugene Chin, Y., Shi, Y., Wu, B., & Zhang, X. (2022). The histone demethylase Kdm6b regulates the maturation and cytotoxicity of TCRαβ. Cell death and differentiation, . https://doi.org/10.1038/s41418-021-00921-w
Zhang, Haohao, et al. "The histone demethylase Kdm6b regulates the maturation and cytotoxicity of TCRαβ." Cell death and differentiation vol. (2022). doi: https://doi.org/10.1038/s41418-021-00921-w
Zhang H, Hu Y, Liu D, Liu Z, Xie N, Liu S, Zhang J, Jiang Y, Li C, Wang Q, Chen X, Ye D, Sun D, Zhai Y, Yan X, Liu Y, Chen CD, Huang X, Eugene Chin Y, Shi Y, Wu B, Zhang X. The histone demethylase Kdm6b regulates the maturation and cytotoxicity of TCRαβ. Cell Death Differ. 2022 Jan 09; doi: 10.1038/s41418-021-00921-w. Epub 2022 Jan 09. PMID: 34999729.
Copy Download .nbib Format: NLM
Dental pulp testing: a review.

International journal of dentistry

Chen E, Abbott PV.
PMID: 20339575
Int J Dent. 2009;2009:365785. doi: 10.1155/2009/365785. Epub 2009 Nov 12.

Dental pulp testing is a useful and essential diagnostic aid in endodontics. Pulp sensibility tests include thermal and electric tests, which extrapolate pulp health from sensory response. Whilst pulp sensibility tests are the most commonly used in clinical practice,...

Cite
Chen E, Abbott PV. Dental pulp testing: a review. Int J Dent. 2009;2009:365785doi: 10.1155/2009/365785.
Chen, E., & Abbott, P. V. (2009). Dental pulp testing: a review. International journal of dentistry, 2009365785. https://doi.org/10.1155/2009/365785
Chen, Eugene, and Abbott, Paul V. "Dental pulp testing: a review." International journal of dentistry vol. 2009 (2009): 365785. doi: https://doi.org/10.1155/2009/365785
Chen E, Abbott PV. Dental pulp testing: a review. Int J Dent. 2009;2009:365785. doi: 10.1155/2009/365785. Epub 2009 Nov 12. PMID: 20339575; PMCID: PMC2837315.
Copy Download .nbib Format: NLM
Phospholipid nanoparticles: Therapeutic potentials against atherosclerosis via reducing cholesterol crystals and inhibiting inflammation.

EBioMedicine

Luo Y, Guo Y, Wang H, Yu M, Hong K, Li D, Li R, Wen B, Hu D, Chang L, Zhang J, Yang B, Sun D, Schwendeman AS, Eugene Chen Y.
PMID: 34879325
EBioMedicine. 2021 Dec 05;74:103725. doi: 10.1016/j.ebiom.2021.103725. Epub 2021 Dec 05.

BACKGROUND: Atherosclerosis-related cardiovascular diseases (CVDs) are the leading cause of mortality worldwide. Cholesterol crystals (CCs) induce inflammation in atherosclerosis and are associated with unstable plaques and poor prognosis, but no drug can remove CCs in the clinic currently.METHODS: We...

Cite
Luo Y, Guo Y, Wang H, et al. Phospholipid nanoparticles: Therapeutic potentials against atherosclerosis via reducing cholesterol crystals and inhibiting inflammation. EBioMedicine. 2021;74:103725doi: 10.1016/j.ebiom.2021.103725.
Luo, Y., Guo, Y., Wang, H., Yu, M., Hong, K., Li, D., Li, R., Wen, B., Hu, D., Chang, L., Zhang, J., Yang, B., Sun, D., Schwendeman, A. S., & Eugene Chen, Y. (2021). Phospholipid nanoparticles: Therapeutic potentials against atherosclerosis via reducing cholesterol crystals and inhibiting inflammation. EBioMedicine, 74103725. https://doi.org/10.1016/j.ebiom.2021.103725
Luo, Yonghong, et al. "Phospholipid nanoparticles: Therapeutic potentials against atherosclerosis via reducing cholesterol crystals and inhibiting inflammation." EBioMedicine vol. 74 (2021): 103725. doi: https://doi.org/10.1016/j.ebiom.2021.103725
Luo Y, Guo Y, Wang H, Yu M, Hong K, Li D, Li R, Wen B, Hu D, Chang L, Zhang J, Yang B, Sun D, Schwendeman AS, Eugene Chen Y. Phospholipid nanoparticles: Therapeutic potentials against atherosclerosis via reducing cholesterol crystals and inhibiting inflammation. EBioMedicine. 2021 Dec 05;74:103725. doi: 10.1016/j.ebiom.2021.103725. Epub 2021 Dec 05. PMID: 34879325.
Copy Download .nbib Format: NLM
Phospholipid nanoparticles: Therapeutic potentials against atherosclerosis via reducing cholesterol crystals and inhibiting inflammation.

EBioMedicine

Luo Y, Guo Y, Wang H, Yu M, Hong K, Li D, Li R, Wen B, Hu D, Chang L, Zhang J, Yang B, Sun D, Schwendeman AS, Eugene Chen Y.
PMID: 34879325
EBioMedicine. 2021 Dec;74:103725. doi: 10.1016/j.ebiom.2021.103725. Epub 2021 Dec 06.

BACKGROUND: Atherosclerosis-related cardiovascular diseases (CVDs) are the leading cause of mortality worldwide. Cholesterol crystals (CCs) induce inflammation in atherosclerosis and are associated with unstable plaques and poor prognosis, but no drug can remove CCs in the clinic currently.METHODS: We...

Cite
Luo Y, Guo Y, Wang H, et al. Phospholipid nanoparticles: Therapeutic potentials against atherosclerosis via reducing cholesterol crystals and inhibiting inflammation. EBioMedicine. 2021;74:103725doi: 10.1016/j.ebiom.2021.103725.
Luo, Y., Guo, Y., Wang, H., Yu, M., Hong, K., Li, D., Li, R., Wen, B., Hu, D., Chang, L., Zhang, J., Yang, B., Sun, D., Schwendeman, A. S., & Eugene Chen, Y. (2021). Phospholipid nanoparticles: Therapeutic potentials against atherosclerosis via reducing cholesterol crystals and inhibiting inflammation. EBioMedicine, 74103725. https://doi.org/10.1016/j.ebiom.2021.103725
Luo, Yonghong, et al. "Phospholipid nanoparticles: Therapeutic potentials against atherosclerosis via reducing cholesterol crystals and inhibiting inflammation." EBioMedicine vol. 74 (2021): 103725. doi: https://doi.org/10.1016/j.ebiom.2021.103725
Luo Y, Guo Y, Wang H, Yu M, Hong K, Li D, Li R, Wen B, Hu D, Chang L, Zhang J, Yang B, Sun D, Schwendeman AS, Eugene Chen Y. Phospholipid nanoparticles: Therapeutic potentials against atherosclerosis via reducing cholesterol crystals and inhibiting inflammation. EBioMedicine. 2021 Dec;74:103725. doi: 10.1016/j.ebiom.2021.103725. Epub 2021 Dec 06. PMID: 34879325; PMCID: PMC8654800.
Copy Download .nbib Format: NLM
Acetyl-CoA production by specific metabolites promotes cardiac repair after myocardial infarction via histone acetylation.

eLife

Lei I, Tian S, Gao W, Liu L, Guo Y, Tang P, Chen E, Wang Z.
PMID: 34939931
Elife. 2021 Dec 23;10. doi: 10.7554/eLife.60311. Epub 2021 Dec 23.

Myocardial infarction (MI) is accompanied by severe energy deprivation and extensive epigenetic changes. However, how energy metabolism and chromatin modifications are interlinked during MI and heart repair has been poorly explored. Here, we examined the effect of different carbon...

Cite
Lei I, Tian S, Gao W, et al. Acetyl-CoA production by specific metabolites promotes cardiac repair after myocardial infarction via histone acetylation. Elife. 2021;10doi: 10.7554/eLife.60311.
Lei, I., Tian, S., Gao, W., Liu, L., Guo, Y., Tang, P., Chen, E., & Wang, Z. (2021). Acetyl-CoA production by specific metabolites promotes cardiac repair after myocardial infarction via histone acetylation. eLife, 10. https://doi.org/10.7554/eLife.60311
Lei, Ienglam, et al. "Acetyl-CoA production by specific metabolites promotes cardiac repair after myocardial infarction via histone acetylation." eLife vol. 10 (2021). doi: https://doi.org/10.7554/eLife.60311
Lei I, Tian S, Gao W, Liu L, Guo Y, Tang P, Chen E, Wang Z. Acetyl-CoA production by specific metabolites promotes cardiac repair after myocardial infarction via histone acetylation. Elife. 2021 Dec 23;10. doi: 10.7554/eLife.60311. Epub 2021 Dec 23. PMID: 34939931.
Copy Download .nbib Format: NLM
Phospholipid nanoparticles: Therapeutic potentials against atherosclerosis via reducing cholesterol crystals and inhibiting inflammation.

EBioMedicine

Luo Y, Guo Y, Wang H, Yu M, Hong K, Li D, Li R, Wen B, Hu D, Chang L, Zhang J, Yang B, Sun D, Schwendeman AS, Eugene Chen Y.
PMID: 34879325
EBioMedicine. 2021 Dec 05;74:103725. doi: 10.1016/j.ebiom.2021.103725. Epub 2021 Dec 05.

BACKGROUND: Atherosclerosis-related cardiovascular diseases (CVDs) are the leading cause of mortality worldwide. Cholesterol crystals (CCs) induce inflammation in atherosclerosis and are associated with unstable plaques and poor prognosis, but no drug can remove CCs in the clinic currently.METHODS: We...

Cite
Luo Y, Guo Y, Wang H, et al. Phospholipid nanoparticles: Therapeutic potentials against atherosclerosis via reducing cholesterol crystals and inhibiting inflammation. EBioMedicine. 2021;74:103725doi: 10.1016/j.ebiom.2021.103725.
Luo, Y., Guo, Y., Wang, H., Yu, M., Hong, K., Li, D., Li, R., Wen, B., Hu, D., Chang, L., Zhang, J., Yang, B., Sun, D., Schwendeman, A. S., & Eugene Chen, Y. (2021). Phospholipid nanoparticles: Therapeutic potentials against atherosclerosis via reducing cholesterol crystals and inhibiting inflammation. EBioMedicine, 74103725. https://doi.org/10.1016/j.ebiom.2021.103725
Luo, Yonghong, et al. "Phospholipid nanoparticles: Therapeutic potentials against atherosclerosis via reducing cholesterol crystals and inhibiting inflammation." EBioMedicine vol. 74 (2021): 103725. doi: https://doi.org/10.1016/j.ebiom.2021.103725
Luo Y, Guo Y, Wang H, Yu M, Hong K, Li D, Li R, Wen B, Hu D, Chang L, Zhang J, Yang B, Sun D, Schwendeman AS, Eugene Chen Y. Phospholipid nanoparticles: Therapeutic potentials against atherosclerosis via reducing cholesterol crystals and inhibiting inflammation. EBioMedicine. 2021 Dec 05;74:103725. doi: 10.1016/j.ebiom.2021.103725. Epub 2021 Dec 05. PMID: 34879325.
Copy Download .nbib Format: NLM
Phospholipid nanoparticles: Therapeutic potentials against atherosclerosis via reducing cholesterol crystals and inhibiting inflammation.

EBioMedicine

Luo Y, Guo Y, Wang H, Yu M, Hong K, Li D, Li R, Wen B, Hu D, Chang L, Zhang J, Yang B, Sun D, Schwendeman AS, Eugene Chen Y.
PMID: 34879325
EBioMedicine. 2021 Dec 05;74:103725. doi: 10.1016/j.ebiom.2021.103725. Epub 2021 Dec 05.

BACKGROUND: Atherosclerosis-related cardiovascular diseases (CVDs) are the leading cause of mortality worldwide. Cholesterol crystals (CCs) induce inflammation in atherosclerosis and are associated with unstable plaques and poor prognosis, but no drug can remove CCs in the clinic currently.METHODS: We...

Cite
Luo Y, Guo Y, Wang H, et al. Phospholipid nanoparticles: Therapeutic potentials against atherosclerosis via reducing cholesterol crystals and inhibiting inflammation. EBioMedicine. 2021;74:103725doi: 10.1016/j.ebiom.2021.103725.
Luo, Y., Guo, Y., Wang, H., Yu, M., Hong, K., Li, D., Li, R., Wen, B., Hu, D., Chang, L., Zhang, J., Yang, B., Sun, D., Schwendeman, A. S., & Eugene Chen, Y. (2021). Phospholipid nanoparticles: Therapeutic potentials against atherosclerosis via reducing cholesterol crystals and inhibiting inflammation. EBioMedicine, 74103725. https://doi.org/10.1016/j.ebiom.2021.103725
Luo, Yonghong, et al. "Phospholipid nanoparticles: Therapeutic potentials against atherosclerosis via reducing cholesterol crystals and inhibiting inflammation." EBioMedicine vol. 74 (2021): 103725. doi: https://doi.org/10.1016/j.ebiom.2021.103725
Luo Y, Guo Y, Wang H, Yu M, Hong K, Li D, Li R, Wen B, Hu D, Chang L, Zhang J, Yang B, Sun D, Schwendeman AS, Eugene Chen Y. Phospholipid nanoparticles: Therapeutic potentials against atherosclerosis via reducing cholesterol crystals and inhibiting inflammation. EBioMedicine. 2021 Dec 05;74:103725. doi: 10.1016/j.ebiom.2021.103725. Epub 2021 Dec 05. PMID: 34879325; PMCID: PMC8654800.
Copy Download .nbib Format: NLM
Differential inflammatory responses of the native left and right ventricle associated with donor heart preservation.

Physiological reports

Lei I, Huang W, Ward PA, Pober JS, Tellides G, Ailawadi G, Pagani FD, Landstrom AP, Wang Z, Mortensen RM, Cascalho M, Platt J, Eugene Chen Y, Lam HYK, Tang PC.
PMID: 34435466
Physiol Rep. 2021 Sep;9(17):e15004. doi: 10.14814/phy2.15004.

BACKGROUND: Dysfunction and inflammation of hearts subjected to cold ischemic preservation may differ between left and right ventricles, suggesting distinct strategies for amelioration.METHODS AND RESULTS: Explanted murine hearts subjected to cold ischemia for 0, 4, or 8 h in...

Cite
Lei I, Huang W, Ward PA, et al. Differential inflammatory responses of the native left and right ventricle associated with donor heart preservation. Physiol Rep. 2021;9(17):e15004doi: 10.14814/phy2.15004.
Lei, I., Huang, W., Ward, P. A., Pober, J. S., Tellides, G., Ailawadi, G., Pagani, F. D., Landstrom, A. P., Wang, Z., Mortensen, R. M., Cascalho, M., Platt, J., Eugene Chen, Y., Lam, H. Y. K., & Tang, P. C. (2021). Differential inflammatory responses of the native left and right ventricle associated with donor heart preservation. Physiological reports, 9(17), e15004. https://doi.org/10.14814/phy2.15004
Lei, Ienglam, et al. "Differential inflammatory responses of the native left and right ventricle associated with donor heart preservation." Physiological reports vol. 9,17 (2021): e15004. doi: https://doi.org/10.14814/phy2.15004
Lei I, Huang W, Ward PA, Pober JS, Tellides G, Ailawadi G, Pagani FD, Landstrom AP, Wang Z, Mortensen RM, Cascalho M, Platt J, Eugene Chen Y, Lam HYK, Tang PC. Differential inflammatory responses of the native left and right ventricle associated with donor heart preservation. Physiol Rep. 2021 Sep;9(17):e15004. doi: 10.14814/phy2.15004. PMID: 34435466; PMCID: PMC8387788.
Copy Download .nbib Format: NLM
Assessing risk post intervention for an acute coronary syndrome: a review of the risk assessment tools and their development.

Contemporary nurse

Scruth E, Worrall-Carter L, Cheng E, Rolley J, Page K.
PMID: 23343227
Contemp Nurse. 2012 Dec;43(1):2-12. doi: 10.5172/conu.2012.43.1.2.

Considerable variability in survival rate after an acute myocardial infarction exists and accurate risk stratification is of significant importance. The American College of Cardiology and the American Heart Association has recommended early risk stratification using several clinical risk scoring...

Cite
Scruth E, Worrall-Carter L, Cheng E, et al. Assessing risk post intervention for an acute coronary syndrome: a review of the risk assessment tools and their development. Contemp Nurse. 2012;43(1):2-12doi: 10.5172/conu.2012.43.1.2.
Scruth, E., Worrall-Carter, L., Cheng, E., Rolley, J., & Page, K. (2012). Assessing risk post intervention for an acute coronary syndrome: a review of the risk assessment tools and their development. Contemporary nurse, 43(1), 2-12. https://doi.org/10.5172/conu.2012.43.1.2
Scruth, Elizabeth, et al. "Assessing risk post intervention for an acute coronary syndrome: a review of the risk assessment tools and their development." Contemporary nurse vol. 43,1 (2012): 2-12. doi: https://doi.org/10.5172/conu.2012.43.1.2
Scruth E, Worrall-Carter L, Cheng E, Rolley J, Page K. Assessing risk post intervention for an acute coronary syndrome: a review of the risk assessment tools and their development. Contemp Nurse. 2012 Dec;43(1):2-12. doi: 10.5172/conu.2012.43.1.2. PMID: 23343227.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 16 entries